AmoyDx(SZ:300685) Sou Hu Cai Jing·2025-07-25 09:45Company Overview - Xiamen Aide Biological Technology Co., Ltd. specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The main products include testing reagents, testing services, and drug clinical research services [1] Financial Performance - For Q1 2025, the company reported revenue of 272 million yuan, representing a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.47 million yuan, showing a year-on-year growth of 40.92% [1] - The sales gross margin stood at 83.48% [1] Market Position - As of July 25, the company's stock closed at 24.13 yuan, with a 1.00% increase, and a rolling price-to-earnings (PE) ratio of 33.61, marking a new low in 95 days [1] - The total market capitalization is 9.448 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 55.41, with a median of 37.94, placing Aide Biological at the 68th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, there are 8 institutions holding shares in Aide Biological, all of which are funds, with a total holding of 1.3993 million shares valued at 3 million yuan [1]